Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.

Clinical advances in hematology & oncology : H&O - 1 May 2018

Domchek Susan M

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Capecitabine
Share to Furans
Share to Indazoles
Share to Ketones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phthalazines

Share to Poly(ADP-ribose) Polymerases

Share to Vinblastine

Share to Vinorelbine

Source

Identifiers

PMID: 29851928

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.PMID 29851928Read ↗

New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.Semantic proximity Read ↗

PARP inhibitors and their evolving role in breast cancer.Semantic proximity Read ↗

The clinical development of inhibitors of poly(ADP-ribose) polymeraseSemantic proximity Read ↗

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.Semantic proximity Read ↗

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseSemantic proximity Read ↗

Association of BRCA mutation status with the efficacy of poly (ADP-ribose) polymerase inhibitors in cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialSemantic proximity Read ↗

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialSemantic proximity Read ↗

Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?Semantic proximity Read ↗

Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673Semantic proximity Read ↗

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.Semantic proximity Read ↗

Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.